英国Rome IV肠易激综合征患者阿片类药物使用率及相关医疗结局
该研究基于英国ContactME-IBS注册库,纳入752例Rome IV肠易激综合征(IBS)患者,调查规律阿片类药物使用率及其对生活质量、心理症状和医疗资源利用的影响。结果显示19.7%的患者规律使用阿片类药物,且使用者生活质量更差、焦虑抑郁比例更高、直接医疗成本更高。
要点
- 约每5例Rome IV IBS患者中就有1例规律使用阿片类药物。
- 阿片使用者疾病特异性和通用生活质量均低于非使用者。
- 阿片使用者焦虑抑郁比例更高、活动受损更重、直接医疗成本更高。
核心结论
- 在社区Rome IV IBS患者中,约五分之一规律使用阿片类药物,且与更差的生活质量、更重的心理损害和更高的直接医疗成本相关。
研究设计与样本
- 研究于2021年7月通过英国ContactME-IBS注册库以电子邮件招募752例Rome IV IBS患者,收集人口学、生活质量、心理症状和医疗利用数据。
主要发现
- 148例(19.7%)报告规律使用阿片类药物,使用率在各IBS亚型间无差异(p=0.10)。
- 阿片使用者的疾病特异性和通用生活质量均低于非使用者(两项分析均p<0.001)。
- 阿片使用者中焦虑或抑郁比例更高(两项分析均p<0.001),整体活动受损更重(p<0.001)。
- 阿片使用者的检查(p=0.003)、IBS相关药物(p<0.001)和计划外住院就诊(p<0.001)的直接医疗成本更高。
- 阿片使用者更愿意接受假想药物治愈IBS症状所带来的死亡风险(p=0.002)。
临床怎么用
- 对Rome IV IBS患者应评估规律阿片使用情况,并关注其生活质量、心理症状和医疗资源利用。
- 鉴于指南不推荐阿片用于包括IBS在内的慢性非恶性疼痛,临床应优化IBS管理以减少阿片使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The United Kingdom (UK) has one of the highest worldwide opioid prescription rates per capita. International guidelines caution against the use of opioids for chronic non-malignant pain, including irritable bowel syndrome (IBS). AIMS: To study the prevalence and impact of regular opioid use among people with Rome IV IBS in community settings in the UK. METHODS: We collected demographic, quality of life (QoL), psychological symptoms, and healthcare utilisation data from 752 people with Rome IV IBS. Participants were recruited via electronic mailshot in July 2021 through ContactME-IBS, a UK registry of persons diagnosed with IBS primarily by a general practitioner or gastroenterologist. RESULTS: Among participants, 148 (19.7%) reported taking an opioid regularly. The prevalence of opioid use did not vary across IBS subtypes (p = 0.10). Disease-specific and generic QoL were lower among opioid users than non-users (p < 0.001, both analyses). Compared with non-users, a greater proportion of opioid users had anxiety or depression (p < 0.001, both analyses) and greater overall activity impairment (p < 0.001). The direct healthcare costs related to investigations (p = 0.003), IBS-related medications (p < 0.001), and unplanned hospital attendances (p < 0.001) were greater among participants who used opioids. Opioid users also expressed a greater willingness to accept the risk of death in return for a cure of IBS symptoms from a hypothetical medication (p = 0.002). CONCLUSION: Approximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non-users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs.
引用
- Butt MF, Goodoory VC, Ng CE, et al. Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom. Aliment Pharmacol Ther. 2025. PMID: 41060048. doi:10.1111/apt.70400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。